Detalles de la búsqueda
1.
Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial.
BMC Cancer
; 22(1): 1348, 2022 Dec 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-36550442
Resultados
1 -
1
de 1
1
Próxima >
>>